Docetaxel

Nazione: Nuova Zelanda

Lingua: inglese

Fonte: Medsafe (Medicines Safety Authority)

Principio attivo:

Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg

Commercializzato da:

REX Medical Ltd

INN (Nome Internazionale):

Docetaxel trihydrate 25.177 mg (equivalent to anhydrous docetaxel 20mg)

Dosaggio:

20 mg/mL

Forma farmaceutica:

Concentrate for infusion

Composizione:

Active: Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection

Confezione:

Vial, glass, Diluent, 1.5 mL

Classe:

Prescription

Tipo di ricetta:

Prescription

Prodotto da:

Cipla Ltd

Indicazioni terapeutiche:

Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.

Dettagli prodotto:

Package - Contents - Shelf Life: Vial, glass, Diluent - 1.5 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 20 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Data dell'autorizzazione:

2006-06-23